Striverdi Respimat approved by the FDA

The FDA has announced the approval of Boehringer Ingelheim’s Striverdi Respimat olodaterol SMI for the treatment of COPD. The FDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) recommended approval of Striverdi Respimat in January 2013. The soft mist inhaler was approved in the EU in October 2013. Curtis Rosebraugh, Director of the Office of Drug Evaluation II . . . Read more

Mystic Pharmaceuticals gets notice of allowance for dry powder delivery tech patent

Mystic Pharmaceuticals has announced that the United States Patent and Trade Office issued a Notice of Allowance for the company’s patent application titled “Medical Devices For Dispensing Powders” (application #13/433,586). The technology is an extension of the company’s VRx2 delivery platform and can be used for nasal, buccal, sublingual and opthalmic powder delivery. In 2013, . . . Read more

AstraZeneca acquires rights to Almirall’s respiratory business

AstraZeneca will pay $875 million initially, plus up to an additional $1.22 billion to acquire development and commercialization rights to Almirall’s entire respiratory drug business. Almirall’s respiratory products include the Eklira/Bretaris/Tudorza aclidinium DPI, an aclidinium/formoterol DPI, and several other inhaled drugs in development. The company’s inhalation R&D subsidiary, Almirall Sofotec, will also become part of . . . Read more